(MDT) Medtronic - Ratings and Ratios

Exchange: NYSE • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00BTN1Y115

Pacemaker, Defibrillator, Stent, Pump, Monitor

Health Care Equipment
Market Cap in USD: 126,581m

IPO / Inception: 1978-01-13
12m vs SPY: 0.72%

EPS (Earnings per Share)

EPS CAGR: -0.20%
EPS Trend: 13.0%

Last SUE: 2.62
Qual. Beats: 4

Revenue

Rev. CAGR: 3.90%
Rev. Trend: 76.3%

Last SUE: 1.26
Qual. Beats: 2

Dividends

Dividend Yield	3.12%
Yield on Cost 5y	2.81%
Yield CAGR 5y	3.46%
Payout Consistency	97.7%
Payout Ratio	50.3%

Risk via 5d forecast
Volatility	19.3%
Value at Risk 5%th	29.6%
Relative Tail Risk	-6.54%

Reward TTM
Sharpe Ratio	0.82
Alpha	11.91
CAGR/Max DD	0.47

Character TTM
Hurst Exponent	0.552
Beta	0.434
Beta Downside	0.541

Drawdowns 3y
Max DD	22.77%
Mean DD	6.18%
Median DD	5.72%

Description: MDT Medtronic December 02, 2025

Medtronic plc (NYSE:MDT) designs, manufactures, and markets a broad range of device-based therapies across five primary segments: Cardiovascular (pacemakers, defibrillators, ablation tools, remote monitoring), Neuroscience (spinal-cord stimulators, brain-modulation systems, drug-infusion implants), Medical Surgical (AI-enhanced video analytics, robotic platforms, stapling and sealing instruments), Diabetes (insulin pumps, CGM sensors, smart pens), and a suite of ancillary products for a wide array of specialists from cardiologists to ENT surgeons. The company operates globally, with a strong footprint in the United States, Ireland, and other international markets.

Key data points to watch: FY 2023 revenue reached roughly $30 billion, with an operating margin near 28%; the Cardiovascular and Diabetes units together contributed over 55% of total sales, reflecting the aging-population tailwinds and rising prevalence of chronic disease. A notable sector driver is the accelerating adoption of remote patient monitoring, which has boosted recurring-revenue streams and improved reimbursement rates under Medicare’s Chronic Care Management program. Additionally, Medtronic’s exposure to the “value-based care” shift means that procedural volume growth may be tempered by bundled-payment models, making cost-efficiency initiatives a critical performance lever.

For a deeper dive into MDT’s valuation metrics, competitive positioning, and scenario analysis, you might explore the detailed research available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (4.76b TTM) > 0 and > 6% of Revenue (6% = 2.09b TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -0.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 40.45% (prev 31.04%; Δ 9.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 7.11b > Net Income 4.76b (YES >=105%, WARN >=100%)

Net Debt (27.82b) to EBITDA (9.27b) ratio: 3.00 <= 3.0 (WARN <= 3.5)

Current Ratio 2.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.29b) change vs 12m ago 0.05% (target <= -2.0% for YES)

Gross Margin 62.27% (prev 65.05%; Δ -2.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 38.32% (prev 36.65%; Δ 1.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 9.03 (EBITDA TTM 9.27b / Interest Expense TTM 710.0m) >= 6 (WARN >= 3)

Altman Z'' 3.32

(A) 0.15 = (Total Current Assets 24.00b - Total Current Liabilities 9.94b) / Total Assets 91.35b

(B) 0.35 = Retained Earnings (Balance) 32.07b / Total Assets 91.35b

(D) 0.65 = Book Value of Equity 27.80b / Total Liabilities 42.49b

Total Rating: 3.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.46

1. Piotroski 5.0pt

2. FCF Yield 3.37%

3. FCF Margin 14.98%

4. Debt/Equity 0.60

5. Debt/Ebitda 3.00

6. ROIC - WACC (= 1.03)%

7. RoE 9.83%

8. Rev. Trend 76.34%

9. EPS Trend 12.99%

What is the price of MDT shares?

As of January 14, 2026, the stock is trading at USD 96.42 with a total of 5,823,166 shares traded.
Over the past week, the price has changed by -3.88%, over one month by -1.46%, over three months by +1.62% and over the past year by +21.61%.

Is MDT a buy, sell or hold?

Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.

Strong Buy: 12
Buy: 5
Hold: 13
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the MDT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	111.1	15.2%
Analysts Target Price	111.1	15.2%
ValueRay Target Price	100.1	3.9%

MDT Fundamental Data Overview January 10, 2026

P/E Trailing = 26.7453
P/E Forward = 16.3934
P/S = 3.6418
P/B = 2.629
P/EG = 3.5006
Beta = 0.729
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 27.62b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 29.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.82b USD (from netDebt column, last quarter)
Enterprise Value = 154.40b USD (126.58b + Debt 29.10b - CCE 1.28b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
EV/FCF = 29.66x (Enterprise Value 154.40b / FCF TTM 5.21b)
FCF Yield = 3.37% (FCF TTM 5.21b / Enterprise Value 154.40b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.69 (Enterprise Value 154.40b / Total Assets 91.35b)
Interest Expense / Debt = 0.62% (Interest Expense 181.0m / Debt 29.10b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 2.42 (Total Current Assets 24.00b / Total Current Liabilities 9.94b)
Debt / Equity = 0.60 (Debt 29.10b / totalStockholderEquity, last quarter 48.65b)
Debt / EBITDA = 3.00 (Net Debt 27.82b / EBITDA 9.27b)
Debt / FCF = 5.34 (Net Debt 27.82b / FCF TTM 5.21b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.25% (Net Income 4.76b / Total Assets 91.35b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.49b)
RoCE = 8.42% (EBIT 6.41b / Capital Employed (Equity 48.49b + L.T.Debt 27.62b))
RoIC = 7.23% (NOPAT 5.54b / Invested Capital 76.64b)
WACC = 6.21% (E(126.58b)/V(155.68b) * Re(7.51%) + D(29.10b)/V(155.68b) * Rd(0.62%) * (1-Tc(0.13)))
Discount Rate = 7.51% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 85.24% ; FCFF base≈5.32b ; Y1≈5.41b ; Y5≈5.92b
Fair Price DCF = 103.0 (EV 159.88b - Net Debt 27.82b = Equity 132.06b / Shares 1.28b; r=6.21% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 12.99 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.34 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS current Year (2026-04-30): EPS=5.65 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+3.0% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.11 | Chg30d=-0.001 | Revisions Net=+3 | Growth EPS=+8.1% | Growth Revenue=+5.7%

Additional Sources for MDT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle